Edition:
India

Benitec Biopharma Ltd (BNTC.OQ)

BNTC.OQ on NASDAQ Stock Exchange Capital Market

3.01USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$3.01
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
10,641
52-wk High
$5.48
52-wk Low
$1.31

Summary

Name Age Since Current Position

Jerel Banks

2017 Non-Executive Chairman of the Board

Gregory West

2016 Chief Executive Officer, Company Secretary

Bryan Dulhunty

2016 Chief Financial Officer

Clifford Holloway

57 2016 Chief Business and Operating Officer

Michael Graham

2012 Chief Scientific Officer

Kevin Buchi

2013 Director

Megan Boston

2016 Non-Executive Director

Peter Francis

2017 Non-Executive Director

Biographies

Name Description

Jerel Banks

Dr. Jerel A. Banks, M.D., Ph.D, is the Non-Executive Chairman of the Board of the Company. He is a Chief Investment Officer of NantVentures. Prior to joining NantVentures, Dr. Banks served as vice president, portfolio manager and research analyst for the Franklin Biotechnology Discovery Fund at Franklin Templeton Investments. Dr. Banks earned an M.D. from the Brown University School of Medicine and a Ph.D. in Organic Chemistry from Brown University and he holds an A.B. in Chemistry from Princeton University.

Gregory West

Mr. Gregory (Greg) West, CA, is Chief Executive Officer, Company Secretary of Benitec Biopharma Limited. He is a Chartered Accountant and over recent years has worked on ASX listing start-ups. He is a Director and Audit Committee Chairman of ITC Limited (a business arm of Wollongong University), IDP Education Pty Ltd, Education Australia Limited, and Sydney International Film School Pty Limited. He completed his studies with Price Waterhouse and worked in senior finance executive roles in investment banking with Bankers Trust, Bain & Company (now Deutsche Bank), NZI, and was CFO at one of the Australian credit union.

Bryan Dulhunty

Mr. Bryan Dulhunty is Chief Financial Officer of the Company., since 1 July 2016. Bryan has 20 years experience in the life sciences sector, and has previously served as Executive Chairman, Non-­-Executive Director, Managing Director, CFO and Company Secretary of a number of listed and non-­-listed biotech companies. Bryan holds a Bachelor of Economics from the University of Sydney and is a Chartered Accountant.

Clifford Holloway

Dr. Cliff Holloway is no longer a Chief Business and Operating Officer of the Company., effective January 2018 (effective early January 2018). He previously served as CEO and Managing Director of Sienna Cancer Diagnostics Limited, Immune System Therapeutics Limited, and Biosceptre International Limited. He was formerly VP Business Development at ASX listed biotechnology company Arana Therapeutics Limited, which was acquired by Cephalon Inc (now Teva Pharmaceuticals) in 2009. Cliff has extensive international experience in biopharmaceutical and healthcare related technologies with a focus on commercialisation and product development. He holds a Bachelor of Pharmacy and a PhD in Medicinal Chemistry from the University of Nottingham, United Kingdom.

Michael Graham

Kevin Buchi

Mr. Kevin Buchi, CPA, is a Director of Benitec Biopharma Ltd since April 11, 2013. He has served as Chief Executive Officer of Cephalon, Inc. through its acquisition by Teva Pharmaceutical Industries in October 2011. After the acquisition, Mr. Buchi served as Corporate Vice President, Global Branded Products of Teva Pharmaceuticals. Mr. Buchi joined Cephalon in 1991 and held various positions, including Chief Operating Officer, Chief Financial Officer and Head of Business Development prior to being appointed CEO. Mr. Buchi currently serves on the Board of Directors of Stemline Therapeutics, Inc., Forward Pharma A/S and Alexza Pharmaceuticals, Inc. Mr. Buchi has served on the Board of Directors of Lorus Therapeutics (Canada), Encysive Pharmaceuticals, Inc., Celator Pharmaceuticals, Inc. and Mesoblast Limited (Australia). Mr. Buchi has served as a Member of the Life Sciences Advisory Board at Safeguard Scientifics, Inc. Mr. Buchi originally trained as a synthetic organic chemist for the Eastman Kodak Company graduating from Cornell University with a Bachelor of Arts degree in chemistry. He holds a Master’s degree in management from the Kellogg Graduate School of Management at Northwestern University and is a Certified Public Accountant.

Megan Boston

Mrs. Megan Joan Boston is the Non­-Executive Director of the Company. Ms Boston was until recently the Managing Director of Omni Market Tide, a listed technology company specialising in shareholder communications, investor relations and voting. Megan is also currently the Acting Chair for statutory authority Adult Multicultural and Education Service (AMES) and a Board member and Chair of the Audit and Risk Committee for the Victorian Human Rights and Equal Opportunity Commission. Previously Ms Boston was a Board Member and Chair of the Finance, Audit and Risk Committee for Beyond Medical Education.

Peter Francis

Mr. Peter Damian Francis is Non-Executive Director of Benitec Biopharma Ltd. He has been on the Company's Board since February 9, 2006, and was previously its Executive Director. He is a partner at Francis Abourizk Lightowlers (FAL), a firm of commercial and technology lawyers with offices in Melbourne, Australia. He is a legal specialist in the areas of intellectual property and licensing and provides legal advice to a number of corporations and research bodies. He is the former director of Xceed Capital Limited.

Basic Compensation